VRCA
Verrica Pharmaceuticals Inc.
There isn't enough reported data to score VRCA yet.
VRCA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
VRCA's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
VRCA PE Valuation
VRCA has no meaningful PE right now: it lost money over the past year.
VRCA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect VRCA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
VRCA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.77 | +$5.89 |
| Q1 2026 | -$1.13 | +$10.25 |
| Q4 2025 | -$1.68 | +$13.10 |
| Q3 2025 | -$2.81 | +$15.67 |
| Q2 2025 | -$7.66 | +$11.34 |
| Q1 2025 | -$11.38 | +$6.32 |
| Q4 2024 | -$14.78 | +$0.02 |
| Q3 2022 | -$10.40 | +$4.20 |
VRCA is still losing money, but far less than before: $1.77 per share over the past year, against $19.00 at its worst in mid-2024.
VRCA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.9M | -54% |
| Q1 2026 | $5M | +46% |
| Q4 2025 | $5.1M | +1380% |
| Q2 2025 | $12.7M | +145% |
| Q1 2025 | $3.4M | -10% |
| Q4 2024 | $344K | -83% |
| Q2 2024 | $5.2M | +2745% |
| Q1 2024 | $3.8M | +10241% |
VRCA's revenue is growing: $6M last quarter, down 54% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -223% | -235 points |
| Q1 2026 | -193% | +43 points |
| Q4 2025 | -141% | +3176 points |
| Q3 2025 | 11% | N/A |
| Q2 2025 | 12% | +306 points |
| Q1 2025 | -236% | +250 points |
| Q4 2024 | -3317% | -2153 points |
| Q2 2024 | -294% | +6089 points |
VRCA's operating margin was −223% last quarter, down 235 points from the same quarter a year ago.
VRCA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$9.2M | +$3.5M |
| Q4 2025 | -$4.6M | +$11.5M |
| Q3 2025 | $9.7M | +$18.3M |
| Q1 2025 | -$12.7M | +$7.3M |
| Q4 2024 | -$16.1M | -$1.3M |
| Q3 2024 | -$8.6M | +$6.3M |
| Q2 2024 | -$16.4M | -$11.6M |
| Q1 2024 | -$19.9M | -$15.3M |
VRCA has burned cash in almost every quarter: −$13M over the past year, against −$54M the year before.
VRCA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +125% | +11.8M shares |
| 3 years | +377% | +16.8M shares |
| 5 years | +753% | +18.8M shares |
| Available history | +756% | +18.8M shares |
VRCA has 21M diluted shares, up 125% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2024 | — |
VRCA Net Leverage
VRCA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
VRCA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.7 | Neutral |
| Stochastic | 10.3 | Oversold |
VRCA's weekly RSI is 40 (neutral) and its Stochastic is 10 (oversold).
VRCA PE vs Healthcare Sector
VRCA has no meaningful PE right now: it lost money over the past year.
VRCA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.78 | 1.6% below |
| 20 week MA | $4.68 | 21% below |
| 50 week MA | $5.80 | 36% below |
| 100 week MA | $5.76 | 35% below |
| 200 week MA | $28.6 | 87% below |
VRCA is in a downtrend: it's below all five of its weekly moving averages, and 87% below its 200-week average.
VRCA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $158.8 | $120.0 | -24% |
| 2021 | $120.0 | $94.3 | -21% |
| 2022 | $94.3 | $25.1 | -73% |
| 2023 | $25.1 | $73.2 | +192% |
| 2024 | $73.2 | $6.84 | -91% |
| 2025 | $6.84 | $8.16 | +19% |
| 2026 YTD | $8.16 | $3.72 | -54% |
VRCA's yearly returns have swung widely, from +192% in 2023 to −91% in 2024. It's down 54% so far in 2026.